Elekta reports major milestones achieved in MR-guided radiotherapy
STOCKHOLM, December 8, 2020 – During the European Society for Radiotherapy and Oncology (ESTRO) and American Society for Radiation Oncology (ASTRO) Annual Meetings, users of the Elekta Unity MR-Linac presented 69 abstracts recounting the past years’ worth of clinical experience with this groundbreaking treatment platform. Since 2014, a total of 460 Unity-related abstracts have been presented during ESTRO, ASTRO and AAPM.
A range of diverse studies, including one from the seven international institutions heading up the MOMENTUM study – titled The Patterns of Care, Tolerability and Safety in the First Year of a Novel High Field MR-Linac – demonstrated the transformative potential of magnetic resonance radiation with Elekta Unity.
“It is simply extraordinary that 23 different clinical indications were treated within the first year of the high-field MR/RT era,” says Dr. John Christodouleas, Elekta'sSenior Vice President of Medical Affairs and Clinical Research. “I think this speaks to the eagerness of clinicians ‘to see what they treat’.”
In addition, this year Elekta Unity users marked the publication of the 300th peer-reviewed article related to the MR-Linac – titled Performance of a Multileaf Collimator System for a 1.5T MR-Linac which evaluated a possible new beam-shaping solution for Elekta Unity.
“The enthusiasm for clinical discovery among Elekta Unity users is truly amazing,” says Lionel Hadjadjeba, President MR-Linac Solutions. “The number and variety of abstracts presented at this year’s meetings really demonstrate the confidence that Unity users have in the utility of MR-guided radiotherapy and reflect their eagerness to explore all clinical possibilities of the system. Each year, it is gratifying to see the pace of Unity investigations accelerate.”
To learn more about Elekta Unity, visit elekta.com/Unity.
# # #
For further information, please contact:
Mattias Thorsson, Vice President, Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Director, Media Relations
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.